SCHEMBL6131298

SCHEMBL6131298

CNCCNCCNCCNCCNC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 2/20 0.39
PRMT6 Q96LA8 2/20 0.39
PRMT8 Q9NR22 2/20 0.39
PRMT3 O60678 1/20 0.39
PRMT1 Q99873 1/20 0.39
LMNA P02545 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CA12 O43570 2/20 0.38
CA6 P23280 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA5B Q9Y2D0 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA3 P07451 1/20 0.38
ALOX15 P16050 1/20 0.38
CA4 P22748 1/20 0.38
CA5A P35218 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL341303 1.00
SCHEMBL16948506 1.00 CARM1 (0.39) CARM1PRMT6PRMT8PRMT3PRMT1
SCHEMBL347764 1.00 CARM1 (0.39) CARM1PRMT6PRMT8PRMT3PRMT1
Hydrochloric Acid SCHEMBL23478121 0.96 KDM4E (0.41) CARM1PRMT6PRMT8PRMT3PRMT1
SCHEMBL18608790 0.89 CYP2C19 (0.50) LMNATDP1ALDH1A1CA12CA6
SCHEMBL5173879 0.86
SCHEMBL18870232 0.86 EPHX1 (0.50) LMNATDP1ALDH1A1CA12CA6
SCHEMBL21003492 0.86 CYP2C19 (0.56) CARM1PRMT6PRMT8PRMT3PRMT1
SCHEMBL18372444 0.86 EPHX1 (0.43) CARM1PRMT6PRMT8PRMT3PRMT1
SCHEMBL16342225 0.86 EPHX1 (0.43) CARM1PRMT6PRMT8PRMT3PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130122050-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2013-05-16 US disclosed
US-20080300189-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2008-12-04 US disclosed
US-6927009-B2 Positive photosensitive composition FUJI PHOTO FILM CO., LTD. (JP) 2005-08-09 US disclosed
EP-1260864-B1 Positive photosensitive composition FUJI PHOTO FILM CO LTD (JP) 2004-08-18 EP disclosed
US-20030077540-A1 Positive photosensitive composition FUJI PHOTO FILM CO., LTD. 2003-04-24 US disclosed
EP-1260864-A1 Positive photosensitive composition FUJI PHOTO FILM CO., LTD. (JP) 2002-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130122050-A1 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE IAPP, LITAF, IGF2BP1 CARM1 4682/4885PRMT6 3053/4885PRMT8 3041/4885
US-20080300189-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION IAPP, PNLIP, AMY2A CARM1 3045/4885PRMT6 2916/4885PRMT8 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.